COVID-19 Updates: What We're Doing to Keep You Safe » COVID-19 Resources » Updated Visitor Policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Intranasal Bevacizumab for HHT-Related Epistaxis
Trial ID or NCT#
Status
RECRUITING
Purpose
This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.
Official Title
Intranasal Bevacizumab for HHT-Related Epistaxis
Eligibility Criteria
- 1. The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT) 2. The patient is to undergo treatment with electrocautery in the operating room under endoscopic visualization 3. The patient is able to give informed consent 4. The patient is at least 18 years old
- 1. The patient has had prior treatment with systemic or nasal bevacizumab within the past year 2. The patient has undergone electrocautery for epistaxis within the 6 months prior to study enrollment 3. The patient is a minor 4. The patient is pregnant 5. The patient is incapable of understanding the consent process 6. The patient has a history of HIV or another known cause of immunosuppression, or is actively taking immunosuppressive medications due to organ transplantation, rheumatoid disease, or other medical conditions.
Investigator(s)
Contact us to find out if this trial is right for you.
CONTACT
Amelia K Clark, MD
View on ClinicalTrials.gov
About this Clinical Trial
Intranasal Bevacizumab for HHT-Related Epistaxis